Japanese Companies Face Diversity Challenges As They Look Outward To Maintain Global Stance
This article was originally published in PharmAsia News
TOKYO - Top executives at Japan's largest pharmaceutical companies say their biggest challenge in becoming global may be to successfully achieve employee diversity at their Japan offices
You may also be interested in...
TOKYO - Takeda Pharmaceutical will not be seeking the generic strategy Pfizer plans in Japan, but may make a generic plunge in South America, says the top executive of the largest Japanese pharma
The Japanese government has decided to revise its drug pricing policies starting in April 2014. Changes include extending a price premium program for two more years, bundling the pricing of similar generic drugs, and reduced pricing on long-listed drugs.